CDK4 and breast carcinoma: Subsequent studies can verify the function of key genes by CRISPR screening and other technologies, and explore their synergistic effects with existing therapeutic regimens (e.g., CDK4/6 inhibitors), to promote the development of precision therapy for breast cancer.